ConforMIS (NASDAQ: CFMS) and Second Sight Medical Products (NASDAQ:EYES) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares ConforMIS and Second Sight Medical Products’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ConforMIS $79.26 million 2.09 -$54.78 million ($1.36) -2.72
Second Sight Medical Products $5.14 million 12.49 -$32.85 million ($0.72) -1.57

Second Sight Medical Products has higher revenue, but lower earnings than ConforMIS. ConforMIS is trading at a lower price-to-earnings ratio than Second Sight Medical Products, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

34.1% of ConforMIS shares are owned by institutional investors. Comparatively, 13.1% of Second Sight Medical Products shares are owned by institutional investors. 9.6% of ConforMIS shares are owned by company insiders. Comparatively, 34.7% of Second Sight Medical Products shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

ConforMIS has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, Second Sight Medical Products has a beta of 3.61, indicating that its share price is 261% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ConforMIS and Second Sight Medical Products, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ConforMIS 0 4 3 0 2.43
Second Sight Medical Products 0 0 1 0 3.00

ConforMIS presently has a consensus target price of $8.25, indicating a potential upside of 122.97%. Second Sight Medical Products has a consensus target price of $5.00, indicating a potential upside of 342.48%. Given Second Sight Medical Products’ stronger consensus rating and higher probable upside, analysts plainly believe Second Sight Medical Products is more favorable than ConforMIS.

Profitability

This table compares ConforMIS and Second Sight Medical Products’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ConforMIS -72.87% -66.61% -49.87%
Second Sight Medical Products -646.89% -168.49% -129.48%

Summary

Second Sight Medical Products beats ConforMIS on 7 of the 13 factors compared between the two stocks.

ConforMIS Company Profile

ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

Receive News & Stock Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related stocks with our FREE daily email newsletter.